Meta-analysis examines relapse risk and treatment in type 1 autoimmune pancreatitis

A systematic review and meta-analysis of 37 studies (5,742 patients) found maintenance therapy was associated with lower relapse risk in type 1 autoimmune pancreatitis (RR 0.58), with longer-term glucocorticoid therapy showing benefit specifically in Asian cohorts. Elevated IgG4 levels, bile duct involvement, and other organ involvement were associated with increased relapse risk, and for relapse treatment rituximab showed the most favorable estimates, though the authors note most comparisons relied on low- or very-low-certainty evidence.

Most relevant for: Patients with type 1 autoimmune pancreatitis being managed for relapse prevention or recurrent disease.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.